Oracle Health Joins the RegenMed Hub

Oracle Health is the latest addition to the RegeneratOR’s Innovation Accelerator, located in the Regenerative Medicine Hub (RegenMed Hub), a rapidly growing regenerative medicine ecosystem based in the Innovation Quarter of Winston-Salem.

Oracle Health is committed to fostering a human-centric, global healthcare ecosystem by unifying data across an open, secure, cloud-based platform supported by applied AI-enabled clinical, payer, and enterprise applications. With these solutions, healthcare organizations can help improve patient outcomes, optimize clinical expertise, and streamline operations.

“Regenerative medicine holds tremendous promise in helping solve some of the most complex medical issues of our time and giving hope to patients dealing with organ failure and other related medical complications,” said Rebecca Laborde, vice president of clinical health innovation at Oracle. “We have the opportunity to come together as a healthcare ecosystem to shape the future of precision medicine and care delivery. That’s why we are here and why we are proud to extend our long collaboration with Wake Forest to bring our clinical, data management, and AI technology and expertise to this worthy and exciting field.”

Advancing the future of patient care

The RegenMed Hub is the destination for regenerative medicine and is powered by WFIRM, Innovation Quarter and ReMDO. The RegendMed Hub offers companies, like Oracle Health, access to unparalleled resources to advance education, products, and manufacturing with the ultimate goal of improving patient care.

Joining the Innovation Accelerator to partner with the RegenMed Development Organization (ReMDO) and the Wake Forest Institute for Regenerative Medicine (WFIRM), the driving forces behind the RegenMed Hub, Oracle Health will bring its decades of data management, clinical, and cloud expertise and technology to advance the field of regenerative medicine. In addition, Oracle’s comprehensive AI portfolio, including its AI infrastructure and generative AI innovations, can support the RegenMed Hub in improving discovery and fostering increased safety and efficiency.

“Our continued partnership with Oracle Health continues to mean great things for the regenerative medicine environment in Winston-Salem, the region and beyond,” said Joshua Hunsberger, PhD, Chief Technology Officer of ReMDO.

Anthony Atala, MD, WFIRM director, credits Oracle Health for trusting the vision for the RegenMed Hub. “Bringing together these types of strong partnerships offers opportunities for growth and advancement for everyone involved. Together, we can advance the regenerative medicine field nationally.”

About the Wake Forest Institute for Regenerative Medicine

The Wake Forest Institute for Regenerative Medicine is recognized as an international leader in translating scientific discovery into clinical therapies, with many world firsts, including the development and implantation of the first engineered organ in a patient. Over 400 people at the Institute, the largest in the world, work on more than 40 different tissues and organs. A number of the basic principles of tissue engineering and regenerative medicine were first developed at the Institute. WFIRM researchers have successfully engineered replacement tissues and organs in all four categories—flat structures, tubular tissues, hollow organs and solid organs—and 15 different applications of cell/tissue therapy technologies, such as skin, urethras, cartilage, bladders, muscle, kidney, and vaginal organs, have been successfully used in human patients. The Institute, which is part of Wake Forest School of Medicine, is located in the Innovation Quarter in downtown Winston-Salem, NC, and is driven by the urgent needs of patients. The Institute is making a global difference in regenerative medicine through collaborations with over 400 entities and institutions worldwide, through its government, academic and industry partnerships, its start-up entities, and through major initiatives in breakthrough technologies, such as tissue engineering, cell therapies, diagnostics, drug discovery, biomanufacturing, nanotechnology, gene editing and 3D printing.

About the RegenMed Development Organization

The mission of the RegenMed Development Organization (ReMDO) is to accelerate the discovery and translation of regenerative medicine therapies. ReMDO is a 501(c)3 non-profit organization that manages a clinical translation initiative that includes thought leaders, representatives from leading US research centers, government representatives, and companies of all sizes. ReMDO conducts research to de-risk technologies and speed up the translation of regenerative medicine to clinical practice and to the global market. ReMDO manages the world’s first and only professional organization dedicated solely to advancing the regenerative medicine field, the Regenerative Medicine Manufacturing Society (RMMS), and the Regenerative Medicine Manufacturing Innovation Consortium (RegMIC), which manages a private-public partnership of industry and academic members focused on scaling up technologies.

Trademarks

Oracle, Java, and MySQL are registered trademarks of Oracle Corporation.